{"url_path":"/sec/rare/8-k/2026-05-18/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1515673/0001193125-26-228639-index.html","accession_number":"0001193125-26-228639","cik":"0001515673","ticker":"RARE","issuer_name":"Ultragenyx Pharmaceutical Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1515673/0001193125-26-228639-index.html","primary_entity_key":"0001515673","primary_entity_name":"Ultragenyx Pharmaceutical Inc."},"word_count":319,"has_tables":true,"body_markdown":"## Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nOn May 14, 2026, the Company held its Annual Meeting. As of the record date of March 23, 2026, 98,317,221 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. A total of 84,786,388 shares of the Company’s common stock were represented in person or by proxy at the Annual Meeting.\n\nProposal No. 1 – Election of Class I Directors\n\nAt the Annual Meeting, the Company’s stockholders elected the Class I director nominees below to the Company’s Board of Directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected. The votes on Proposal 1 were as follows:\n\n \n\nClass I Director Nominees\n\nVotes For\n\nVotes Withheld\n\nBroker Non-Votes\n\nEmil D. Kakkis, M.D., Ph.D.\n\n72,517,613\n\n1,056,885\n\n11,211,890\n\nShehnaaz Suliman, M.D.\n\n65,801,638\n\n7,772,860\n\n11,211,890\n\nDaniel G. Welch\n\n66,301,426\n\n7,273,072\n\n11,211,890\n\n \n\nProposal No. 2 – Approval of the Third A&R 2023 Plan\n\nAt the Annual Meeting, the Company’s stockholders approved the Third A&R 2023 Plan. The votes on Proposal 2 were as follows:\n\n \n\nVotes For\n\nVotes Against\n\nAbstentions\n\nBroker Non-Votes\n\n50,659,150\n\n22,888,600\n\n26,748\n\n11,211,890\n\n \n\nProposal No. 3 – Ratification of Selection of Independent Registered Accounting Firm\n\nAt the Annual Meeting, the Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. The votes on Proposal 3 were as follows:\n\n \n\nVotes For\n\nVotes Against\n\nAbstentions\n\n84,551,399\n\n221,802\n\n13,187\n\n \n\nProposal No. 4 – Advisory (Non-Binding) Vote to Approve Executive Compensation\n\nAt the Annual Meeting, the Company’s stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its “named executive officers” as described in the Proxy Statement. The votes on Proposal 4 were as follows:\n\n \n\nVotes For\n\nVotes Against\n\nAbstentions\n\nBroker Non-Votes\n\n70,945,277\n\n2,594,517\n\n34,704\n\n11,211,890"}